A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age

Infertility Clinical Trial

Official title:

Exploratory Study to Determine the Effect of Lutropin Alfa on Embryo Quality and Their Implantation in Women of Advanced Reproductive Age

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01075815
• Other study ID #: 700642-500
• Secondary ID: 2008-002281-55
• Status: Terminated
• Phase: Phase 2
• First received: February 24, 2010
• Last updated: January 20, 2014
• Start date: November 2008
• Est. completion date: October 2010

Study information

• Verified date: January 2014
• Source: Merck KGaA
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios
• Study type: Interventional

Clinical Trial Summary

This is a multicentric, open, randomized, comparative trial aimed to assess the influence of recombinant luteinizing hormone (r-LH) supplementation during controlled ovarian stimulation (COS) in advanced reproductive age in terms of improved embryo competence which allows to transfer less embryos to avoid high grade multiple pregnancy without reducing the pregnancy rate.

Description:

This study will be carried out by the Grupo de Interés de Salud Embrionaria (GISE) group (part of the Spanish Fertility Society) who uses strict criteria to select the embryos most suitable for successful transference.

OBJECTIVES

Primary objective:

• To determine the benefit of r-LH supplementation in COS prior to in-vitro fertilization (IVF)/intracytosolic sperm injection (ICSI) in advanced reproductive age, in terms of embryo competence to implant, as compared against no r-LH supplementation

Secondary objectives:

To evaluate the benefit of r-LH supplementation in COS, in terms of:

• follicular development

• length of the stimulation

• oocyte number and their maturity

• fertilization rate

• embryo number and quality

• gestational sacs

• abortion

• ongoing pregnancies

• local and systemic safety of r-LH administration

The study will consist of 2 groups randomized in 1:1 ratio and each subject would be followed up until the confirmation of her pregnancy status. Each subject will be administered gonadotropin releasing hormone (GnRH) agonist subcutaneously daily from previous mid luteal phase to r-hCG administration as a standard practice to achieve down regulation. Each subject will also be administered recombinant follicle stimulating hormone (r-FSH) at a starting dose of 300 IU from S1 up to ovarian stimulation completion (r-hCG day) as a part of standard practice. In addition to the above concurrent therapies, one group will be administered experimental treatment (Luveris®) and the other group (control group) will not be administered any other drug (control treatment) during the stimulation period from stimulation start (S1) up to ovarian stimulation completion or stimulation cancellation respectively. Ovarian stimulation on an average takes 11 days and it is expected that stimulation period will not be extended beyond 15 days. A single injection of r-hCG will be administered intramuscularly or subcutaneously after the last injection of Luveris or r-FSH to achieve final follicular maturation. After, 34-36 hours of administration of r-hCG OPU will be done for oocyte retrieval and embryo transfer (ET) will be conducted within 5 days from OPU. Subjects will also be provided luteal support with natural progesterone and will be followed until delivery or miscarriage. Ultrasound and estradiol (E2) assessment of follicular growth will be conducted at various time points during the stimulation period with or without treatment adjustment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 76
• Est. completion date: October 2010
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 35 Years and older

Eligibility

Inclusion Criteria:

• Pre-menopausal female subject aged greater than (>) 35 years

• Subjects with baseline FSH serum level less than or equal to (<=) 10 IU/liter (l), LH and E2 levels within local normal range and plasma prolactin levels < 30 nanogram/milliliter (ng/ml)

• Subjects with regular spontaneous menstrual cycles of 25-35 days

• Subjects with infertility justifying IVF/ICSI-ET treatment

• Subjects programmed for COS with r-FSH under GnRH agonist protocol

• Sperm from current male partner suitable for IVF/ICSI according to local lab, unless sperm donor is foreseen

• Subjects with presence of both ovaries

• Subjects whose uterine cavity is able to sustain embryo implantation or pregnancy

• Subjects with normal papanicolaou test (PAP) smear within previous 3 years

• Subjects with body mass index (BMI) < 30 at stimulation start

• Subjects who receive confirmation of not being pregnant by a negative beta-hCG test (urine or blood) prior to starting r-FSH administration

• Subjects willing and able to comply with the protocol for the duration of the study

• Subjects who have given informed consent prior to any study-related procedure not part of normal medical care

Exclusion Criteria:

• Subjects or her male partners who are known to be human immunodeficiency virus, hepatitis B virus or hepatitis C virus positive

• Subjects with any clinically significant systemic disease; tumors of the hypothalamus and pituitary gland; ovarian, uterine or mammary cancer; hormonal abnormality and/or medical, biochemical, hematological condition which in the judgment of the investigator may interfere with gonadotropin treatment

• Subjects with more than 2 previous assisted reproductive technologies (ART) cycles

• Subjects in which previous cycles were cancelled due to poor response (< 3 antral follicles after 15 day of stimulation)

• Subjects with cryopreserved embryos from previous ART cycles

• Subjects with unexplained gynecological bleeding

• Subjects with polycystic ovaries, ovarian enlargement or cyst of unknown etiology

• Subjects known to have any contraindication to being pregnant and/or carrying pregnancy to term

• Subjects with known allergy to gonadotrophin preparations or any of the excipients

• Subjects known to have any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years

• Subjects with previous entry into this study or simultaneous participation in another clinical drug trial

• Subjects who have refused to or inability to comply with the protocol

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Infertility
• Ovulation Induction

Intervention

Drug:
• Recombinant human luteinizing hormone (rhLH)

• Recombinant follicle-stimulating hormone (rFSH)

Locations

Country	Name	City	State
Spain	FivMadrid, C/ Marqués de Urquijo, 26,	Madrid

Sponsors (2)

Lead Sponsor	Collaborator
Merck KGaA	Merck, S.L., Spain

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Implantation Rate	Implantation rate was measured as the number of gestational sacs observed, divided by the number of embryos transferred.	Day 35-42 post ovum pick-up (OPU) (34-38 hours post recombinant human choriogonadotropin day {end of stimulation cycle}[approximately 28 days])	No
Secondary	Mean Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day		r-hCG day (end of stimulation cycle [approximately 28 days])	No
Secondary	Mean Number of Oocytes Retrieved	Mean number of oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days]) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.	34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])	No
Secondary	Number of Mature Oocytes Retrieved	Number of mature oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days]) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. The nuclear maturity was evaluated based on the presence of a germinal vesicle (GV) or whether oocytes were in metaphase I (Meta-I) or II (Meta-II) stage.	34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])	No
Secondary	Number of Fertilized Oocytes (2 Pronuclei [PN])	Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of two 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN.	34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])	No
Secondary	Number and Quality of Embryos	Embryos were graded according to Spanish Association for the Study of Reproductive Biology (ASEBIR) criteria into different categories: (A) optimal quality with maximum capacity for implantation, (B) good quality with a high capacity for implantation, (C) regular with low possibility of implantation and (D) poor quality with very little possibility of implantation.	Day 2-3 post OPU (34-38 hours post r-hCG day {end of stimulation cycle}[approximately 28 days])	No
Secondary	Number of Participants With Biochemical Pregnancies	Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy.	2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])	No
Secondary	Number of Participants With Clinical Pregnancies	Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.	2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])	No
Secondary	Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH)		2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])	No
Secondary	Estradiol (E2) Levels on r-hCG Day		r-hCG day (end of stimulation cycle [approximately 28 days])	No
Secondary	Number of Ovarian Stimulation Days	Ovarian stimulation included from first rFSH injection (S1) until day on which r-hCG was administered (r-hCG day). This period was divided into 2 parts: the first period in which 300 International Unit (IU) rFSH dose was constant and which covered from S1 to Day 4 of stimulation period (S4); the second period in which the rFSH dose could be adjusted depending on the ovarian response and which began on S4 and finished on the day on which the criteria for administration of r-hCG to induce the final follicular maturation were met.	S1 up to r-hCG day (end of stimulation cycle [approximately 28 days])	No
Secondary	Number of Recombinant Human Choriogonadotropin (r-hCG) Cycles Cancelled Due to Poor Response	Poor response was defined as 3 or less follicles of greater than or equal to 12 mm developing following at least 7 days of study treatment.	Up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])	No
Secondary	Total Number of Births	Total number of births per reporting group was calculated.	Up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])	No
Secondary	Number of Participants With Adverse Events (AEs)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.	Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])	Yes
Secondary	Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)	OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.	Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])	Yes
Secondary	Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)	OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.	Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])	Yes